Nasdaq pgen.

PGEN Latest Pre Market Trades. Select time range to see more trades: Pre-Market Time (ET) Pre-Market Price. Pre-Market Share Volume. 09:29:37. $2.24. 7. 09:27:22.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Nasdaq Futures. 15511.25-27.25 (-0.18%). Dow Jones Futures. 34865.0074.00 (0.21 ... NASDAQ:PGEN · Buy Candidate. Precigen, Inc. Stock Price (Quote). NASDAQ Stock ...Based on analysts offering 12 month price targets for PGEN in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

What: Shares of Intrexon (PGEN 1.75%), a developer of gene-based therapies for a variety of diseases, surged as much as 24% during Thursday's trading session as a direct result of the spreading ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million .

Precigen (NASDAQ: PGEN) $1.26 (-3.8%) -$0.05 Price as of November 8, 2023, 4:00 p.m. ET Key Data Points Current Price $1.26 Daily Change (-3.8%) -$0.05 Day's Range $1.21 - $1.31 Previous Close...VinFast Auto Ltd. Ordinary Shares. NVIDIA Corporation Common Stock. $485.09 -8.46 -1.71%. Find the latest dividend history for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.

PGEN Biotech sector needs some love, this stock right here has had significant insider buying within the last 3 months. Although the right idea is to wait for profitability, regular investors should keep an eye on this t enter a long position if the price were to drop to $ 1.33 USD again in value.Over the past 30 days, the shares of Precigen Inc (NASDAQ:PGEN) have changed 11.21%. Short interest in the company has seen 16.25 million shares shorted with days to cover at 9.69. Wall Street analysts have a consensus price target for the stock at $9.00, which means that the shares’ value could jump 86.78% from current levels.Intrexon's shares nosedived today on a worse-than-expected third-quarter earnings release.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...PGEN Pre-Market Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary ...

Based on analysts offering 12 month price targets for PGEN in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Apr 20, 2020 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

GERMANTOWN, Md., Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen, Inc NASDAQ: PGEN (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and ...

Insider trading information is an indicator that can be used to gain valuable insights and as a reflection of the prospect of the company.The public float for PGEN is 128.23M, and currently, short sellers hold a 12.67% ratio of that floaft. The average trading volume of PGEN on November 30, 2023 was 1.32M shares. PGEN) stock’s latest price update. Precigen Inc (NASDAQ: PGEN) has experienced a rise in its stock price by 4.09 compared to its previous closing price of 1.10.Analyst Price Forecast Suggests 711.97% Upside. As of May 11, 2023, the average one-year price target for Precigen is 9.26. The forecasts range from a low of 6.06 to a high of $14.70. The average ...(NASDAQ: PGEN) Precigen currently has 248,919,096 outstanding shares. With Precigen stock trading at $1.16 per share, the total value of Precigen stock (market capitalization) is $288.75M . Precigen stock was originally listed at a …(NASDAQ: PGEN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%. What is PGEN's Price Target? According to 2 Wall Street analyst s that have issued a 1 year PGEN price target, the average PGEN price target is $10.00 , with the highest PGEN stock price forecast at $14.00 and the lowest PGEN stock ...

Nasdaq Futures. 15511.25-27.25 (-0.18%). Dow Jones Futures. 34865.0074.00 (0.21 ... NASDAQ:PGEN · Buy Candidate. Precigen, Inc. Stock Price (Quote). NASDAQ Stock ...Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell ...

Precigen (NASDAQ: PGEN) is not a big biotech company. Its market capitalization is just $277 million. Its market capitalization is just $277 million. However, it’s got an interesting history.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Intrexon's shares nosedived today on a worse-than-expected third-quarter earnings release.PGENNASDAQ See on Supercharts Overview News Ideas Financials Technicals Forecast PGEN chart Today −8.68% 5 days 10.50% 1 month 2.31% 6 months −16.29% Year to date −29.62% 1 year −42.75% 5 years …PRECIGEN, INC. (PGEN) SPO - NASDAQ.com.Is Precigen (NASDAQ:PGEN) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company ...GERMANTOWN, Md., Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

See the latest Precigen Inc stock price (PGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Webull offers PGEN Ent Holdg (PGEN) historical stock prices, in-depth market analysis, NASDAQ: PGEN real-time stock quote data, in-depth charts, free PGEN options chain data, and a fully built financial calendar to help you invest smart.

VinFast Auto Ltd. Ordinary Shares. NVIDIA Corporation Common Stock. $485.09 -8.46 -1.71%. Find the latest dividend history for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com. Precigen Inc (NASDAQ:PGEN) is a company dedicated to creating innovative gene and cell therapies to improve the lives of patients.In their latest updates, they have shared financial information ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Aug 28, 2023 · Precigen ( NASDAQ: PGEN) is a clinical-stage biopharmaceutical firm focusing on next-generation gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases ... Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...In 2023, Precigen (NASDAQ: PGEN), a clinical-stage company, is garnering high expectations from Wall Street analysts. The average price target is $8.77 on last look, translating into over 618% upside.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...GERMANTOWN, Md., March 1, 2022 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results. “In 2021, Precigen was able to demonstrate significant progress in our …Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...What Is Precigen's Debt? You can click the graphic below for the historical numbers, but it shows that as of June 2022 Precigen had US$198.7m of debt, an increase on US$177.3m, over one year. On ...Precigen has not achieved profitability for ten years; its revenues peaked back in 2017 at $219M. Mean analyst estimates today suggest a drop in revenue for the year ending December 2023 to $24.8 ...

SIGA Technologies, Inc. (NASDAQ:SIGA), Genmab A/S (NASDAQ:GMAB), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), and Precigen, Inc. (NASDAQ:PGEN) are some of the highest growth and profitable ...In January 2023, four company executives bought PGEN stock. The largest of those buys was from executive chairman (and former CEO) Randall Kirk. Kirk purchased 11,428,571 shares of PGEN stock for ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Instagram:https://instagram. why nvda stock is downbest health insurance california for young adultsmpc stock forecasthow much a gold bar worth Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...A. The latest price target for Immunome ( NASDAQ: IMNM) was reported by Cantor Fitzgerald on Monday, March 20, 2023. The analyst firm set a price target for 8.00 expecting IMNM to rise to within ... what brokers use mt5clean energy funds Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...May 10, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... kinross stock Feb 1, 2023 · The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million . Precigen, Inc. Common Stock (PGEN) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.